PAVmed Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PAVM research report →
Price Chart
About the company
PAVmed Inc. operates as a U. S.
- CEO
- Lishan Aklog
- IPO
- 2016
- Employees
- 41
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on PAVM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.08M
- P/E
- -0.13
- PEG
- 0.00
- P/S
- 64.83
- P/B
- 0.29
- EV/EBITDA
- -1.29
- Div Yield
- 0.00%
- Gross Margin
- -237.84%
- Op Margin
- -19315.54%
- Net Margin
- -13339.19%
- ROE
- -58.07%
- ROIC
- -109.34%
Latest fiscal year · YoY change
- Revenue
- $71.00K-97.6%
- Gross Profit
- $-252,000+91.7%
- Op Income
- $-21,806,000
- Net Income
- $401.00K-99.0%
- EPS
- $-5.63-105.7%
- OCF Growth
- +84.5%
- FCF Growth
- +84.4%
- 52W High
- $28.44
- 52W Low
- $1.10
- 50D MA
- $2.55
- 200D MA
- $6.01
- Beta
- 0.54
- RSI (14)
- 28
- Avg Volume
- 23.70K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
PAVmed said its portfolio is hitting multiple milestones, led by Medicare reimbursement for Lucid’s EsoGuard and continued progress at Veris, PortIO, and Octeris.· November 13, 2026
- Lucid secured Medicare reimbursement for EsoGuard and has started getting paid at the full Medicare rate; October was a record month for test volume.
- Veris enrollment at Ohio State nearly doubled from July to September, and the implantable monitor remains on track for an FDA 510(k) submission in early 2027.
- PortIO had a successful initial FDA call, and management said a 510(k) path may be possible, which could shorten timeline and reduce capital needs.
- Octeris’ next-generation probe is complete, FDA pre-submission is planned for this month, and enrollment in the clinical validation study is expected to begin in January.
- Financially, cash was $8.9 million at September 30, burn was about $2.8 million in the quarter, and non-GAAP loss improved to $1.2 million from $1.7 million in the second quarter.
PAVmed reported cash of $8.9 million at September 30, including $5.3 million of restricted cash. Third-quarter burn was approximately $2.8 million versus $2.7 million in the second quarter. Preliminary GAAP net loss was $13 million before non-controlling interest and preferred dividends, compared with a prior-year loss of $6 million, driven largely by a $9.6 million net fair-value charge versus $4.5 million a year ago. Preliminary GAAP net loss attributable to common stockholders was $11.8 million, and non-GAAP loss was $1.2 million, improved from $1.7 million in the second quarter. Non-GAAP OPEX was $5.6 million, down about $480,000 sequentially. The company did not give formal quarterly or full-year revenue guidance, but said Lucid’s Medicare reimbursement should allow it to quickly scale commercial activity, while Veris aims for FDA submission in early 2027 and Octeris expects an FDA pre-submission package this month with enrollment starting in January.
Lishan Aklog framed the quarter around multiple portfolio inflection points, calling Lucid’s Medicare reimbursement for EsoGuard a “critical and transformational milestone.” He said PAVmed is focused on turning OSU into a template for Veris commercialization, while also progressing PortIO and Octeris through FDA interactions. His tone was constructive and optimistic, but grounded in execution details, especially around regulatory pathways, workflow adoption, and using each program to build long-term shareholder value.
Dennis McGrath focused on liquidity, balance sheet items, and the quarter’s non-cash accounting effects. He said cash was $8.9 million, restricted cash was $5.3 million, and the company received $2.8 million from its ATM during the quarter; a new ATM with A.G.P. for up to $9.4 million is fully available. He highlighted a $15 million senior secured note with a 15% interest rate, noted the minimum cash covenant was satisfied, and said the collateral coverage covenant was not met at September 30 because of Lucid’s share-price decline, though the lender waived it through the SEC filing date. He also explained that the quarter’s larger GAAP loss was mainly from non-cash fair-value changes tied to Lucid shares and the note, while non-GAAP loss improved to $1.2 million and non-GAAP OPEX fell to $5.6 million.
Analysts pressed on why Veris enrollment was accelerating, and management said it was mainly the staged rollout across departments at The James Cancer Center, supported by strong leadership buy-in and ongoing training/onboarding. Asked about expansion beyond OSU, management said there is some interest from other cancer centers but they are not aggressively pursuing them yet because they want to learn from OSU and package the workflow playbook before broader rollout after implantable clearance. On PortIO, management said the FDA is now being asked to consider a 510(k) path instead of De Novo, citing a successful first-in-human study and a narrower intended use; if accepted, that would likely mean a shorter and less capital-intensive path, though it is still to be determined. On Octeris, management explained it sits after EsoGuard in the care pathway and aims to use imaging rather than molecular testing to better identify dysplasia during confirmatory endoscopy.
The call’s bullish case is that PAVmed now has several identifiable catalysts rather than a single story. Lucid has a live reimbursement pathway and is already getting paid, Veris is building operating know-how at a major cancer center, PortIO may qualify for a faster regulatory route, and Octeris is advancing toward clinical testing. Management repeatedly emphasized that these programs could create multiple commercialization opportunities over the next several quarters.
The main risks are execution, regulatory, and financing. PAVmed still had only $8.9 million of cash at quarter-end, burned about $2.8 million in the quarter, and is managing covenant pressure on its senior note tied to Lucid share value. Veris, PortIO, and Octeris are still pre-clearance or early commercialization projects, so timelines could slip if FDA feedback is less favorable or if onboarding and validation take longer than expected.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 51.9%
- Shares Outstanding
- 8.00M
- Float Shares
- 4.15M
of shares held by institutions
20 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 342.17K | ▲ 133.80K |
| First Manhattan Co. LLC. | 332.91K | ▲ 309.11K |
| Vanguard Capital Management LLC | 63.21K | ▲ 1.60K |
| Geode Capital Management, LLC | 29.47K | ▼ 7.21K |
| Vanguard Fiduciary Trust Co | 25.61K | 0 |
| Blackrock, Inc. | 15.54K | ▼ 1.55K |
| Cibc Private Wealth Group LLC | 836 | 0 |
| Parkside Financial Bank & Trust | 246 | ▲ 246 |
| Morgan Stanley | 160 | ▼ 3 |
| Cwm, LLC | 157 | ▼ 4.51K |
| Ubs Group AG | 51 | ▼ 6 |
| Wells Fargo & Company/Mn | 45 | 0 |
Held by 9 ETFs
Biggest fund positions in PAVM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 2, 26 | Lee Victoria Tou-ho | other | 70,000 |
| Mar 24, 26 | Lee Victoria Tou-ho | other | 0 |
| Mar 27, 26 | Tasso Partners, LLC | other | 0 |
| Feb 3, 26 | Tasso Partners, LLC | other | 0 |
| Apr 2, 26 | Aklog Lishan | other | 350,000 |
| Apr 2, 26 | MCGRATH DENNIS M | other | 180,000 |
| Apr 2, 26 | Glennon Michael J | other | 13,930 |
| Apr 2, 26 | Baxter Timothy E | other | 13,930 |
| Apr 2, 26 | White Debra | other | 13,930 |
| Apr 2, 26 | Sparks Ronald M | other | 13,930 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PAVM coverage
Recent articles, reports, and earnings notes.
No research on PAVM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PAVM report →PAVmed Inc. (PAVM) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
prnewswire.com · Nov 13
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
prnewswire.com · Nov 12
Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year
prnewswire.com · Nov 5
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
prnewswire.com · Nov 4
Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study
prnewswire.com · Nov 3
PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026
prnewswire.com · Oct 30
Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
prnewswire.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.